Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) PT at $13.14

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given an average rating of “Hold” by the twelve research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $13.1429.

JSPR has been the subject of a number of research reports. TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, May 15th. Royal Bank Of Canada set a $3.00 price target on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a research report on Friday, May 15th. UBS Group initiated coverage on shares of Jasper Therapeutics in a report on Monday, March 23rd. They set a “neutral” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Tuesday, April 21st.

Hedge Funds Weigh In On Jasper Therapeutics

A number of hedge funds have recently modified their holdings of JSPR. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics in the 4th quarter worth about $26,000. Panagora Asset Management Inc. acquired a new position in Jasper Therapeutics in the fourth quarter worth approximately $35,000. Acadian Asset Management LLC acquired a new position in Jasper Therapeutics in the first quarter worth approximately $46,000. Voleon Capital Management LP bought a new position in Jasper Therapeutics during the third quarter valued at approximately $50,000. Finally, Jain Global LLC bought a new position in Jasper Therapeutics during the fourth quarter valued at approximately $79,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Jasper Therapeutics Stock Performance

Shares of NASDAQ:JSPR opened at $0.45 on Wednesday. The firm has a 50 day simple moving average of $0.80 and a 200 day simple moving average of $1.24. Jasper Therapeutics has a 52 week low of $0.42 and a 52 week high of $7.19. The company has a market cap of $12.66 million, a PE ratio of -0.14 and a beta of 3.00.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.08. On average, equities analysts predict that Jasper Therapeutics will post -1.81 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.